

Bridging the Sciences 2006
HIV, HBV, HCV and Emerging Viruses

Scientific Program

Abstract

Wednesday, May 31, 2006

14:00 Welcome
Raymond Schinazi *Emory University/VA Medical Center, USA*

SESSION 1:

Chairs: Robert Murphy *Northwestern University, USA*
Gilles Gosselin *Laboratoire Cooperatif Idenix-CNRS-UM II, France*

Plenary Lectures

14:10 Bridging chemistry to HIV, HBV, HCV and poxvirus infections: 001
The phosphonate bridge
Erik De Clercq *Rega Institute for Medical Research, Belgium*

14:50 HIV reverse transcriptases: structural basis for inhibition and drug resistance 002
David Stammers *University of Oxford, UK*

15:30 **Break**

Invited Speakers

16:00 The emerging impact of research universities on antiviral drug discovery 003
Dennis Liotta *Emory University, USA*

16:20 The use of animal models to address critical issues in viral therapy 004
Tom North *University of California, USA*

16:40 Overview of new directions in HCV therapy 005
Jean-Michel Pawlotsky *Henri Mondor University Hospital, France*

17:00 Clinical trial design, end points, and regulatory issues
Michael Manns *Medizinische Hochschule Hannover, Germany*

Thursday, June 1, 2006

SESSION 2:

Chairs: Stephen Locarnini *VIDRL, Australia*
Dennis Liotta *Emory University, USA*

Plenary Lectures

8:30 Protease inhibitors for chronic hepatitis C 006
Stefan Zeuzem *Saarland University Hospital, Germany*

9:10 Cell culture systems for the hepatitis C virus and their use for antiviral drug 007
development
Ralf Bartenschlager *University of Heidelberg, Germany*

9:50 **Break**

Invited Speakers

10:20 From start to finish: lessons learned in hepatitis therapeutics
Yves Benhamou *Hôpital Pitié-Salpêtrière, France*

10:40 Co-infections with HIV, HBV and HCV 008
Robert Murphy *Northwestern University, USA*

11:00	New drugs in HIV treatment Christine Katlama	<i>Groupe Hospitalier Pitié-Salpêtrière, France</i>	
11:20	Treatment of HIV drug resistance; TMC114 and TMC125 Diego Miralles	<i>Tibotec BVBA, Belgium</i>	009
Oral Abstracts			
11:40	Activation of antiviral nucleotide analogues by human NMP kinases: importance of the alpha-phosphate substitution Dominique Deville-Bonne	<i>Université Paris 6, France</i>	010
11:50	Synthesis of oxazolopyrimidines targeting an anti-HIV activity Luigi Agrofoglio	<i>Université d'Orléans, France</i>	011
12:00	Lunch on your own		
SESSION 3:			
Chairs:	Yves Benhamou George Lau	<i>Hôpital Pitié-Salpêtrière, Paris, France</i> <i>The University of Hong Kong/Queen Mary Hospital, Hong Kong</i>	
Plenary Lectures			
13:30	Subversion of Toll-like receptor functions by hepatitis C virus in dendritic cells Daniel Lamarre	<i>Centre de recherche du CHUM - Hôpital Saint-Luc, Canada</i>	012
14:10	VTX-950: A NS3•4a protease inhibitor that specifically targets HCV John Randle	<i>Vertex Pharmaceuticals, Inc., USA</i>	013
14:50	Break		
Invited Speakers			
15:20	Preclinical characteristics of ITMN-191, an orally active macrocyclic inhibitor of the HCV NS3/4A protease Lawrence Blatt	<i>InterMune, Inc., USA</i>	014
15:40	Clinical trial experience of Viramidine: an oral pro-drug of ribavirin for the treatment of hepatitis C Brian Murphy	<i>Valeant Pharmaceuticals International, USA</i>	015
16:00	Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients George Hill	<i>Roche, USA</i>	016
16:20	From CCR5 to maraviroc: the discovery of a new investigational antiretroviral agent Manos Perros	<i>Pfizer Global R&D, UK</i>	017
16:40	Vicriviroc use in novel antiretroviral regimens Lisa Dunkle	<i>Schering-Plough Research Institute, USA</i>	018
17:00	Design of antiviral agents with enhanced pharmacokinetics John Erickson	<i>Sequoia Pharmaceuticals, Inc., USA</i>	019
Oral Abstract			
17:20	Modulation of endoplasmic reticulum (ER) calcium signalling affects hepatitis C virus (HCV) protein expression and replication Patrizia Paterlini-Bréchet	<i>INSERM, France</i>	020

Friday, June 2, 2006

Abstract

SESSION 4:

Chairs: Daria Hazuda *Merck Research Labs, USA*
Françoise Brun-Vézinet *Hôpital Bichat-Claude Bernard, France*

Plenary Lectures

8:30 Hepatitis B virus and the innate immune response: A new paradigm for therapeutic intervention 021
Stephan Locarnini *VIDRL, Australia*

9:10 Suppressing HBV replications with new drugs and combinations 022
George Lau *The University of Hong Kong/Queen Mary Hospital, Hong Kong*

9:50 **Break**

Invited Speakers

10:20 Discovery of L-dT (telbivudine) as a new potent nucleoside analogue for the treatment of chronic hepatitis B 023
Gilles Gosselin *Laboratoire Cooperatif Idenix-CNRS-UM II, France*

10:40 Prevention of HCC by antiviral drugs 024
Massimo Colombo *IRCCS Maggiore Hospital, Italy*

11:00 HIV, HBV and HCV - different viruses with different kinetics and clinical implications 025
Avidan Neumann *Bar-Ilan University, Israel*

Oral Abstracts

11:20 A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBsAg carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues 026
Gulendam Bozdayi *Gazi University, Turkey*

11:30 Novel peptidomimetic andimers inhibit mutated HIV-1 proteases 027
Michèle Reboud-Ravaux *CNRS-University Paris 6, France*

11:40 Utility and complementarity of replicative phenotyping for drug discovery and in diagnostics 028
Vincent Vidal *InPheno AG, Switzerland*

11:50 High throughput assay screening for inhibitors of ion channels including HCV p7, HIV-1 Vpu and 'flu H5N1 M2 029
Wesley Black *The Macfarlane Burnet Institute for Medical Research and Public Health, Australia*

12:00 **Lunch on your own**

SESSION 5:

Chairs: Raymond Schinazi *Emory University/VA Medical Center, USA*
David Stammers *University of Oxford, UK*

Plenary Lectures

13:30 Drug resistance, vaccine development, and beyond 030
Douglas Richman *University of California, San Diego/VA Medical Center, USA*

14:10 The other HIV-1 enzymes: integrase and beyond 031
Daria Hazuda *Merck Research Labs, USA*

14:50 **Break**

Invited Speakers

15:20	Maintenance/simplification therapy including original studies using abacavir, nevirapine, efavirenz and atazanavir Jose Gatell <i>Hospital Clinic, Spain</i>	
15:40	HCV drug development - lessons learned from HIV Doug Mayers <i>Boehringer Ingelheim Pharmaceuticals, Inc., USA</i>	032
16:00	Similarities and differences between HIV-1 and HIV-2 drug resistance Françoise Brun-Vézinet <i>Hôpital Bichat-Claude Bernard, France</i>	033
16:20	Discovery and development of an oral influenza drug: "TAMIFLU" Choung Kim <i>Gilead Sciences, USA</i>	034

Closing Plenary Lecture

16:40	Emergence of novel retroviruses Walid Heneine <i>Centers for Disease Control and Prevention, USA</i>	035
-------	---	-----

Closing Remarks

Yves Benhamou *Hôpital Pitié-Salpêtrière, France*